The trial got published in NEJM. It confirms survival advantage and skeletal mets advantage with abiraterone for metastatic disease similar to the Latitude study. This will certainly be an option for metastatic disease at presentation (along with docetaxel until comparative studies comparing docetax...

The authors argue (including Dr. James in his presentation): that lack of heterogenity between M0 and M1 patients means the magnitude of impact on long-term outcomes would be similar for non-metastatic disease (even though few deaths in M0 patients thus far). These data, while pobably not enough to ...

Approximately 40% of patients in both arms received radiotherapy. Of note, while ADT was given for at least 2 years, radiotherapy was mandatory for patients with node-negative, nonmetastatic disease at 6 to 9 months after randomization and optional for patients with node-positive, nonmetastatic dise...